Contra-indicated in patients with ocular or periocular infections.
Ranibizumab-nuna (Byooviz) is biosimilar to Ranibizumab. Approved 09/17/2021
Ranibizumab-Eqrn (Cimerli) is biosimilar to Ranibizumab. Approved 08/02/2022
- TRADE NAME: Lucentis (Genentech)
- INDICATIONS: Neovascular (wet) age-related macular degeneration, macular edema (following retinal vein occlusion)
- CLASS: Angiogenesis inhibitor / antiangiogenic agent, Monoclonal antibody, Vascular endothelial growth factor (VEGF) inhibitor / antagonist
- HALF-LIFE: 9 days
- FDA APPROVAL DATE: 06/30/2006
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
- See adverse reactions attributed to class:
Angiogenesis inhibitor / antiangiogenic agent
Vascular endothelial growth factor (VEGF) inhibitor / antagonist
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ranibizumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 10/10/2024
